Imke Kraai1, Arjen de Vries2, Karin Vermeulen3, Vincent van Deursen2, Martje van der Wal4, Richard de Jong5, René van Dijk6, Tiny Jaarsma4, Hans Hillege3, Ivonne Lesman3. 1. Department of Cardiology, University Medical Center Groningen, University of Groningen, The Netherlands. Electronic address: i.h.kraai@umcg.nl. 2. Department of Cardiology, University Medical Center Groningen, University of Groningen, The Netherlands. 3. Department of Epidemiology, University Medical Center Groningen, University of Groningen, The Netherlands. 4. Linköping University, Faculty of Health Sciences, Department of Social and Welfare Studies, Linköping, Sweden. 5. Department of Cardiology, Wilhelmina Hospital Assen, The Netherlands. 6. Department of Cardiology, Cavari Clinics Groningen, The Netherlands.
Abstract
AIM: It is still unclear whether telemonitoring reduces hospitalization and mortality in heart failure (HF) patients and whether adding an Information and Computing Technology-guided-disease-management-system (ICT-guided-DMS) improves clinical and patient reported outcomes or reduces healthcare costs. METHODS: A multicenter randomized controlled trial was performed testing the effects of INnovative ICT-guided-DMS combined with Telemonitoring in OUtpatient clinics for Chronic HF patients (IN TOUCH) with in total 179 patients (mean age 69 years; 72% male; 77% in New York Heart Association Classification (NYHA) III-IV; mean left ventricular ejection fraction was 28%). Patients were randomized to ICT-guided-DMS or to ICT-guided-DMS+telemonitoring with a follow-up of nine months. The composite endpoint included mortality, HF-readmission and change in health-related quality of life (HR-QoL). RESULTS:In total 177 patients were eligible for analyses. The mean score of the primary composite endpoint was -0.63 in ICT-guided-DMS vs. -0.73 in ICT-guided-DMS+telemonitoring (mean difference 0.1, 95% CI: -0.67 +0.82, p=0.39). All-cause mortality in ICT-guided-DMS was 12% versus 15% in ICT-guided-DMS+telemonitoring (p=0.27); HF-readmission 28% vs. 27% p=0.87; all-cause readmission was 49% vs. 51% (p=0.78). HR-QoL improved in most patients and was equal in both groups. Incremental costs were €1360 in favor of ICT-guided-DMS. ICT-guided-DMS+telemonitoring had significantly fewer HF-outpatient-clinic visits (p<0.01). CONCLUSION:ICT-guided-DMS+telemonitoring for the management of HF patients did not affect the primary and secondary endpoints. However, we did find a reduction in visits to the HF-outpatient clinic in this group suggesting that telemonitoring might be safe to use in reorganizing HF-care with relatively low costs.
RCT Entities:
AIM: It is still unclear whether telemonitoring reduces hospitalization and mortality in heart failure (HF) patients and whether adding an Information and Computing Technology-guided-disease-management-system (ICT-guided-DMS) improves clinical and patient reported outcomes or reduces healthcare costs. METHODS: A multicenter randomized controlled trial was performed testing the effects of INnovative ICT-guided-DMS combined with Telemonitoring in OUtpatient clinics for Chronic HFpatients (IN TOUCH) with in total 179 patients (mean age 69 years; 72% male; 77% in New York Heart Association Classification (NYHA) III-IV; mean left ventricular ejection fraction was 28%). Patients were randomized to ICT-guided-DMS or to ICT-guided-DMS+telemonitoring with a follow-up of nine months. The composite endpoint included mortality, HF-readmission and change in health-related quality of life (HR-QoL). RESULTS: In total 177 patients were eligible for analyses. The mean score of the primary composite endpoint was -0.63 in ICT-guided-DMS vs. -0.73 in ICT-guided-DMS+telemonitoring (mean difference 0.1, 95% CI: -0.67 +0.82, p=0.39). All-cause mortality in ICT-guided-DMS was 12% versus 15% in ICT-guided-DMS+telemonitoring (p=0.27); HF-readmission 28% vs. 27% p=0.87; all-cause readmission was 49% vs. 51% (p=0.78). HR-QoL improved in most patients and was equal in both groups. Incremental costs were €1360 in favor of ICT-guided-DMS. ICT-guided-DMS+telemonitoring had significantly fewer HF-outpatient-clinic visits (p<0.01). CONCLUSION: ICT-guided-DMS+telemonitoring for the management of HF patients did not affect the primary and secondary endpoints. However, we did find a reduction in visits to the HF-outpatient clinic in this group suggesting that telemonitoring might be safe to use in reorganizing HF-care with relatively low costs.
Authors: Wei Ning Chi; Courtney Reamer; Robert Gordon; Nitasha Sarswat; Charu Gupta; Emily White VanGompel; Julie Dayiantis; Melissa Morton-Jost; Urmila Ravichandran; Karen Larimer; David Victorson; John Erwin; Lakshmi Halasyamani; Anthony Solomonides; Rema Padman; Nirav S Shah Journal: Appl Clin Inform Date: 2021-12-29 Impact factor: 2.342
Authors: Edita Lycholip; Ina Thon Aamodt; Irene Lie; Toma Šimbelytė; Roma Puronaitė; Hans Hillege; Arjen de Vries; Imke Kraai; Anna Stromberg; Tiny Jaarsma; Jelena Čelutkienė Journal: Patient Prefer Adherence Date: 2018-06-26 Impact factor: 2.711
Authors: Muhammad Hamza; Jelmer Alsma; John Kellett; Mikkel Brabrand; Erika F Christensen; Tim Cooksley; Harm R Haak; Prabath W B Nanayakkara; Hanneke Merten; Bo Schouten; Immo Weichert; Christian P Subbe Journal: Resusc Plus Date: 2021-04-10
Authors: Ingvild Margreta Morken; Marianne Storm; Jon Arne Søreide; Kristin Hjorthaug Urstad; Bjørg Karlsen; Anne Marie Lunde Husebø Journal: J Med Internet Res Date: 2022-02-15 Impact factor: 7.076